1. Introduction {#sec1}
===============

AP is one of the most common gastrointestinal diseases, and patients need hospitalization \[[@B1]\]. Although most patients are mild, about 20% of patients develop moderate or severe pancreatitis with surrounding pancreas tissue necrosis or multiple organ failure \[[@B2]--[@B4]\]. The overall mortality rate of AP patients is about 2%, but close to 30% in patients with persistent organ system failure. An increased risk of pancreatic cancer in AP patients was observed in a nationwide, population-based matching cohort study \[[@B5]\]. Furthermore, 17%--22% of AP patients have the possibility of recurrence, and 8%--16% may develop chronic pancreatitis \[[@B6], [@B7]\]. Therefore, early diagnosis is necessary for AP patients.

As a pancreatic inflammatory disease, AP has become one of the leading causes of gastrointestinal disease admission in the United States and many other countries. And the incidence rate demonstrates an increasing trend. There are many factors that cause the disease, such as gallstones, smoking, and alcohol abuse \[[@B8], [@B9]\]. Of course, about 10% of patients have no cause, and they are idiopathic pancreatitis. The patients have usually a sudden onset with severe persistent abdominal pain, and 80% of patients are accompanied by vomiting. Pain may radiate to the back, usually in the lower chest area. Therefore, it is critical to carry out some treatments within 48 hours, such as fluid resuscitation, analgesia, and nutritional support \[[@B10]\]. Despite the continuous improvement in diagnostic techniques, early diagnosis is still difficult for clinicians.

Therefore, it is critical to explore early diagnostic biomarkers of AP \[[@B11]\]. More and more evidence has confirmed that circRNAs could play an important role in many diseases. CircRNAs are produced by reverse splicing of precursor mRNAs from exons of thousands of genes in eukaryotes \[[@B12]\]. At the same time, circRNAs can be secreted into blood, saliva, and other body fluids as potential biomarkers for disease prediction \[[@B13]\]. However, the function of most circRNAs remains largely unknown. In the ceRNA mechanism, microRNAs (miRNAs) are important posttranscriptional regulators of gene expression that act on target sites in the untranslated region of messenger RNA (mRNA) by direct base pairing. The circRNA can act as a miRNA sponge to affect the activity of miRNAs in the regulation of mRNA expression \[[@B14], [@B15]\]. At the same time, circRNA abnormalities can lead to a variety of diseases. For example, the circMTO1 could inhibit the progression of hepatocellular carcinoma by promoting p21 expression, acting as a sponge of oncogenic miR-9 \[[@B16]\]. However, to date, no study has explored the expression of circRNAs in the blood of patients with AP. Therefore, our aim was to explore accurate biomarkers and then diagnose patients with AP as soon as possible by detecting biomarkers in the patients\' blood.

2. Materials and Methods {#sec2}
========================

2.1. Patient Information and Diagnostic Criteria {#sec2.1}
------------------------------------------------

We reviewed 60 patients who were diagnosed with AP from April 2018 to September 2018 at the First Affiliated Hospital of China Medical University (Shenyang, China). In addition, we recruited 30 subjects who underwent routine health checks at the First Affiliated Hospital of China Medical University and showed no signs of disease as a control group. According to the "Guidelines for the diagnosis and treatment of acute pancreatitis (2014)," clinically meets 2 of the following 3 characteristics to diagnose AP: (1) abdominal pain consistent with AP; (2) serum amylase and/or lipase activity is at least 3 times higher than the upper limit of normal; (3) abdominal imaging examination is consistent with AP imaging changes.

In clinical treatment, mild acute pancreatitis (MAP) patients receive only relatively simple treatment, while severe acute pancreatitis (SAP) patients usually require intensive care. Therefore, we selected 30 MAP and 30 SAP patients to diagnose AP patients with early stage. Currently, common scoring standards are the APPACHE II scoring standard, the MCTSI scoring standard, and BISAP scoring standard. MAP diagnostic criteria were good response to fluid supplementation, without organ failure, and local or systemic complications, recovery within 1-2 weeks. And APACHE-II score \<8 points or the MCTSI score \<4 points or BISAP \<2 are MAP. Diagnostic criteria for SAP were with persistent organ failure (48 h or more). And APACHE-II score ≥8 points or MCTSI score ≥4 points or BISAP ≥2 are SAP.

The exclusion criteria were as follows: \<18 years of age, pregnant and lactating women, taking anticoagulant drugs, blood system diseases, tumors, liver disease, and gastrointestinal bleeding patients. The patients\' information is shown in [Table 1](#tab1){ref-type="table"}.

Then we selected 3 patients with MAP and 3 healthy participants for microarray analysis. The study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University, and informed consent was obtained from all subjects. [Figure 1](#fig1){ref-type="fig"} depicts further experimental design details.

2.2. RNA Extraction and CircRNA Microarray Analysis {#sec2.2}
---------------------------------------------------

We collected whole blood from 3 MAP patients and 3 healthy participants. Total RNA from each sample was quantified using a NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA). Sample preparation and microarray hybridization were performed based on the standard protocol of Arraystar. Briefly, total RNA was digested with Rnase R (Epicenter, Inc.) to remove linear RNA and enrich for circular RNA. Then, the enriched circular RNA was amplified by a random priming method (Arraystar Super RNA Labeling Kit; Arraystar) and transcribed into fluorescent cRNA. The labeled cRNA was hybridized to Arraystar Human circRNA Array V2 (8 × 15 K, Arraystar). The labeled cRNA was purified by RNeasy Mini Kit (Qiagen). The concentration and specific activity of the labeled cRNA (pmol Cy3/*μ*gcRNA) were measured by NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA). 1 *μ*g of each labeled cRNA was fragmented by adding 5 *μ*l of 10× blocking agent and 1 *μ*l of 25× fragmentation buffer; then the mixture was heated at 60°C for 30 minutes, and finally 25 *μ*l of 2× hybridization buffer was added to dilute the labeled cRNA. 50 *μ*l of the hybridization solution was dispensed into a spacer slide and assembled onto a circRNA expression microarray slide. Slides were incubated for 17 hours at 65°C in Agilent Hybridization Oven. The hybridization array was fixed and scanned using an Agilent Scanner G2505C wash.

Agilent Feature Extraction software (version 11.0.1.1) was utilized to analyze the acquired array images. Quantile normalization and subsequent data processing were performed using the R software limma package (R version 3.1.2).

2.3. Differential Expression Analysis {#sec2.3}
-------------------------------------

A scatter plot is a visualization method used to assess circRNA expression variation. Differentially expressed circRNAs with statistical significance (FC ≥ 1.5 and *P* values ≤0.05) were identified utilizing fold change cutoffs and volcano plots, respectively. Among them, *P* value was calculated utilizing the unpaired *t*-test. Differentially expressed circRNAs between the two samples were identified by fold change filtration. Hierarchical clustering was performed to show the distinguishable circRNA expression patterns in the samples. Shanghai Kangcheng Biological Engineering Co., Ltd. of the People\'s Republic of China conducted microarray work.

2.4. qPCR Verification {#sec2.4}
----------------------

Total RNA was extracted from the whole blood of 30 healthy participants, 30 MAP patients, and 30 SAP patients according to standard procedures. Total RNA was reverse-transcribed into cDNA kits (Roche, Penzberg, Germany) using random primers and Transcriptor First Strand cDNA Synthesis according to the manufacturer\'s instructions. 6 differentially expressed circRNAs were measured by qPCR using a ViiA 7 Real-time PCR System (Applied Biosystems). The reaction conditions were as follows: 95°C for 10 minutes and 40 cycles of 95°C for 10 seconds, 60°C for 60 seconds. RNA levels were normalized to human *β*-actin. All qPCR reactions were performed in triplicate. Different primers were designed for circRNAs, rather than the more commonly used convergent primers ([Figure 2](#fig2){ref-type="fig"}). [Table 2](#tab2){ref-type="table"} lists all the primers.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analyses were performed using SPSS (version 19.0; IBM, Armonk, NY, United States) and GraghPad Prism (version 7.0; GraphPad Software, La Jolla, CA, United States). The relative expression level of each circRNA was expressed by fold change and converted into 2^−ΔΔCt^. The expression difference in circRNAs among SAP, MAP patients, and healthy individuals and between MAP patients and posttreatment serum samples was assessed using the *t*-test. To assess the diagnostic value, ROC curve was established. The cut-off value of each circRNA was analyzed by using SPSS software. Area under the ROC curves (AUCs) were calculated to evaluate the ability of the differentially expressed circRNAs. Due to the relative small sample size for ROC analysis, the statistical power was calculated using PASS (version 15.0), under the following conditions: *α* = 0.05, AUC0 = 0.5, and *n* = 30. *P* value \< 0.05 was considered statistically significant.

2.6. The Construction of ceRNA Network {#sec2.6}
--------------------------------------

By combining cotargeted miRNAs, we constructed a ceRNA network by cytoscape package of R language \[[@B17], [@B18]\]. In addition to measuring the number of common miRNAs, each ceRNA pair was subjected to a hypergeometric test, which was defined by four parameters: (i) *N* is the total number of miRNAs used to predict the target; (ii) *K* is the The number of miRNAs interacting with the selected gene; (iii) *n* is the number of miRNAs that interact with the candidate ceRNA of the selected gene; (iv) the miRNA number common between the two genes \[[@B19]\]. This test used the following formula to calculate the *P* value:$$\begin{matrix}
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3. Results {#sec3}
==========

3.1. Identification of Differentially Expressed CircRNAs {#sec3.1}
--------------------------------------------------------

To investigate the expression profile of circRNAs in AP, we used microarray analysis to perform circRNA expression profiling in the blood of patients with MAP and matched normal humans. The box plot visualized the dataset distribution of circRNAs. After normalization, [Figure 3(a)](#fig3){ref-type="fig"} depicts that the log 2 ratios in the three pairs of samples are almost identical. At the same time, we used a scatter plot of the circRNA expression profile to evaluate the change between the two groups ([Figure 3(b)](#fig3){ref-type="fig"}), where the values of the *X* and *Y* axes are the average normalized signal values (log 2 scaling) of the sample set. And the green line is the fold line, and the circRNA above the top green line and below the bottom green line indicates that the circRNA change between the two samples is more than 1.5 times. Next, volcano maps were used to identify differentially expressed circRNAs that were statistically significant between the two groups and are shown in [Figure 3(c)](#fig3){ref-type="fig"}. Among them, the vertical lines correspond to 1.5 times up and down, and the horizontal lines represent *P*=0.05. The red dot indicates upregulated circRNAs while blue represents downregulated circRNAs. We found 51 differentially expressed circRNAs in patients with MAP (FC ≥ 1.5 and *P* values ≤0.05) compared with normal subjects. Among them, [Table 3](#tab3){ref-type="table"} shows 25 upregulated circRNAs and 26 downregulated circRNAs are described in [Table 4](#tab4){ref-type="table"}. Next, we clustered all the different circRNAs to characterize the expression pattern of circRNA. The results are exhibited in [Figure 4](#fig4){ref-type="fig"}. Among them, red stand for elevated and green represents downregulated circRNAs.

3.2. qPCR Verification {#sec3.2}
----------------------

To verify differentially expressed circRNAs in AP, we made qPCR. And we selected three upregulated circRNAs including hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 and three downregulated circRNAs including hsa_circRNA_002532, hsa_circRNA_059665, and hsa_circRNA_104156. We validated the expression of three downregulated circRNAs in MAP and normal humans. And the results are shown in [Figure 5](#fig5){ref-type="fig"}. *P* values are 0.008 (hsa_circRNA_002532), \<0.0001 (hsa_circRNA_059665), and \<0.0001(hsa_circRNA_104156), respectively.

To further explore the relationship between the three upregulated circRNAs and disease severity, we compared the expression levels in healthy individuals, MAP, and SAP patients, respectively. As shown in [Figure 6](#fig6){ref-type="fig"}, we found that as the condition worsened, the expression levels of hsa_circRNA_101015 (*P* value was 0.0003, \<0.0001, and \<0.0001, respectively), hsa_circRNA_101211 (*P* value was 0.0014, 0.0478, and \<0.0001, respectively), and hsa_circRNA_103470 (*P* value was 0.001, \<0.0001, and \<0.0001) also increased significantly. Then we validated the expression levels of three upregulated circRNAs in MAP patients and MAP after treatment. The results are demonstrated in [Figure 7](#fig7){ref-type="fig"}. After treatment, the expression levels of hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 in MAP were significantly declined (*P* value \<0.0001).

3.3. ROC Analysis of hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 in Patients with AP {#sec3.3}
-------------------------------------------------------------------------------------------------------

The ROC curve was constructed to assess the diagnostic significance of the three elevated circRNAs ([Figure 8](#fig8){ref-type="fig"}). RUCs of hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 MAP patients with healthy people were 0.768 (95% CI, 0.651--0.886, *P* \< 0.001, power = 0.97119), 0.731 (95% CI, 0.605--0.857, *P*=0.002, power = 0.90168), 0.770 (95% CI, 0.653--0.887, *P* \< 0.001, power = 0.97340), respectively. RUC of the three circRNAs combination was 0.838 (95% CI, 0.738--0.937, *P* \< 0.001, power = 0.99954). The above results show that hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 can be used as biomarkers to diagnose AP at early stage.

3.4. The Construction of ceRNA Network {#sec3.4}
--------------------------------------

Recent evidence suggests that circular RNA plays a crucial role in the regulation of miRNA-mediated gene expression regulation by isolating miRNAs. Their interaction with disease-associated miRNAs suggests that circular RNA is important for disease regulation \[[@B20]\]. To assess the potential function of circRNA, we investigated potential miRNAs that bind to circRNA. Then we constructed a ceRNA network for the six differentially expressed circRNAs. In the ceRNA network, there are 241 nodes and 831 edges ([Figure 9](#fig9){ref-type="fig"}). Among them, for all nodes, red represents microRNAs, light-blue color represents protein_coding RNAs, and at the same time, brown color represents circular RNAs. Considering all edges, T-shape arrow represents directed relationships, while edges without arrow stand for undirected relationships. Specific details are shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

4. Discussion {#sec4}
=============

AP is an inflammatory process of the pancreas and has become an increasingly common clinical disease. In the second or third week of the disease, 40--70% of patients develop infectious necrosis and are the leading cause of late death \[[@B21]\]. In the United States, AP accounts for \$2.5 billion in medical expenses, and the number of hospital admissions is about 275,000 per year \[[@B22]\]. Because of the high mortality rate of 20--30% in severe cases of AP, early detection of patients who may need to be transferred to the intensive care unit (ICU) is critical. For patients with AP, accurate diagnosis, appropriate triage, high-quality supportive care, monitoring and treatment of complications, and prevention of recurrence are also critical \[[@B23]\]. The evaluation of biomarkers helps to further improve the identification of high-risk patients. In general, the clinical treatment decisions for AP depend primarily on the severity of the condition. MAP is usually self-limiting and does not cause death. However, SAP can develop rapidly, leading to multiple organ failure and becoming life threatening. Therefore, the treatment of MAP patients is relatively simple and requires only a short hospitalization, while the treatment of SAP patients usually involves intensive care. Whether it is MAP or SAP, quick and accurate diagnosis is still very difficult.

Accurate diagnosis of AP may allow for effective treatment to begin earlier. At present, the accuracy of different scoring systems is not high, and a unique model is needed \[[@B24]\]. There are several laboratory tests such as blood urea nitrogen, creatinine, and hematocrit \[[@B25]\]. However, there is virtually no laboratory test that consistently and accurately predicts the severity of AP earlier \[[@B26], [@B27]\]. Many predictive systems use CT findings, but CT evidence of SAP lags behind clinical findings, and early CT studies may underestimate the severity of the disease. The scoring system is complex and cumbersome; therefore, these scoring systems are not a substitute for the clinician\'s experience assessment.

In recent years, circRNA has received wide attention as a new class of endogenous and regulatory noncoding RNAs. At the same time, with the widespread use of RNA sequencing (RNA-seq) technology and bioinformatics prediction, a large number of circRNAs have been identified. So far, no study has examined the role of circRNA in AP. Considering that circRNA is involved in a variety of diseases, it is necessary to explore differences in the expression of circRNA in patients with AP. Microarrays are an effective tool for analyzing circRNA. Therefore, in our study, we made full use of microarray technology and selected three patients with MAP and three healthy individuals. Our aim was to explore the differential expression of circRNA in the patients\' blood with AP to diagnose AP patients as soon as possible. As a result, we found 25 upregulated circRNAs and 26 downregulated circRNAs. The vast majority of circRNAs have not been studied and require more in-depth exploration.

To further validate the six circRNAs in AP, we performed qPCR analysis. The results of qPCR studies provide novel biomarkers for molecular diagnosis and evaluation in AP. Three circRNAs including hsa_circRNA_002532 hsa_circRNA_059665, and hsa_circRNA_104156 were downregulated in MAP compared with healthy individuals. Three upregulated circRNAs including hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 significantly increased expression levels as the condition worsens. Furthermore, the expression levels of hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 were significantly reduced after treatment. This result suggests that the above three circRNAs may be involved in the development of AP and show promise as potential biomarkers for AP. To evaluate the specificity and sensitivity of the hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470, we performed a ROC curve for further validation. The RUC was 0.768, 0.731, and 0.770, respectively, and the combined RUC values of the three circRNAs were 0.838. Therefore, the three circRNAs can be used as diagnostic biomarkers for AP with high sensitivity.

However, the pathogenesis of AP remains unknown. Therefore, the 6 differentially expressed circRNAs were selected to construct a ceRNA network including three upregulated hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 and three downregulated hsa_circRNA_002532 hsa_circRNA_059665, and hsa_circRNA_104156. In the ceRNA network, we found a complex regulatory network for the above six circRNAs. However, the above six differentially expressed circRNAs excluding hsa_circRNA_104156 have not been reported. Considering that circRNAs can act as sponges of miRNAs, it is of importance to explore miRNAs in AP. More importantly, miRNAs play a critical role in the progression of AP. For example, a previous study found that miR-92b, miR-10a, and miR-7 are downregulated in the blood of patients with AP and can be used to distinguish between patients with AP and healthy cases. In addition, the expression level of miR-551b-5p distinguishes between MAP and SAP \[[@B28]\]. However, these six circRNAs cannot interact with above these miRNAs. In the ceRNA network, hsa_circRNA_101015 could become sponges of several miRNAs such as hsa-miR-135a/b and hsa-miR-543. It has been reported that hsa-miR-135 was upregulated in the serum of mice with acute pancreatitis \[[@B29]\]. Furthermore, it has reported that hsa-miR-135a/b binding polymorphism can reduce the expression of CD133 and reduce the risk of lung cancer and improve the prognosis of patients \[[@B30]\]. Abnormalities in hsa-miR-543 can lead to increased proliferation of multiple cancers, such as esophageal cancer, prostate cancer, and osteosarcoma \[[@B31]--[@B33]\]. In the ceRNA network, hsa-miR-135 could be a target of hsa_circRNA_101015. It has been found that hsa-miR-216a was downregulated in the serum of mice with acute pancreatitis \[[@B34]\]. Elevated serum hsa-miR-122 has been considered as a noninvasive marker for acute pancreatitis, which could become a target miRNA of hsa_circRNA_059665 as shown in the ceRNA network \[[@B35]\]. Moreover, hsa-miR-148a has been validated to be lowly expressed in acute pancreatitis \[[@B36]\]. Our results showed that hsa-miR-148a could be a potential target miRNA of hsa_circRNA_059665. Furthermore, hsa-miR-148a could inhibit autophagy through IL-6/STAT3 axis in AP in acute pancreatitis. According to the ceRNA network, hsa_circRNA_104156 could be considered as a sponge of hsa-miR-148a.

Therefore, we inferred that the six circRNAs could participate in pathogenic process of AP. However, specific research mechanisms need to be explored. In the future, we would continue to research the molecular mechanisms of hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 in AP.

5. Conclusion {#sec5}
=============

After microarray analysis and qPCR, we found three downregulated circRNAs including hsa_circRNA_002532, hsa_circRNA_059665, and hsa_circRNA_104156 and three upregulated circRNAs including hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 in the blood of AP patients. The ceRNA network revealed that the six circRNAs could play a critical role in AP. Therefore, elevated hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 can be used as biomarkers in the blood to diagnose AP at early stage. The molecular mechanisms of elevated hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 in the pathological processes of AP would be explored in our further experiments.
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![A flow chart of the experimental design.](BMRI2020-2419163.001){#fig1}

![Schematic representation of polymerase chain reaction primers for specific detection of circular transcripts. Different polymerase chain reaction primers were designed for circRNA, rather than the more commonly used convergent primers.](BMRI2020-2419163.002){#fig2}

![Overview of microarray features. (a) Box plots are datasets that quickly visualize circRNAs spectra (zheng: normal person\'s blood; test: blood of patients with acute pancreatitis). (b) Scatter plot showing circRNA expression variation between blood samples from patients with AP and matched normal persons. (c) Volcano maps of differentially expressed circRNAs.](BMRI2020-2419163.003){#fig3}

![The hierarchical cluster of the differentially expressed circRNAs.](BMRI2020-2419163.004){#fig4}

![qPCR analysis of circRNA expression levels in MAP and healthy individuals including hsa_circRNA_002532, hsa_circRNA_059665, and hsa_circRNA_104156 (^*∗*^*P* \< 0.05; ^*∗∗∗*^*P* \< 0.001; ^*∗∗∗∗*^*P* \< 0.0001).](BMRI2020-2419163.005){#fig5}

![qPCR analysis of circRNA expression levels in healthy human, MAP, SAP patients including hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 (^*∗*^*P* \< 0.05; ^*∗∗∗*^*P* \< 0.001; ^*∗∗∗∗*^*P* \< 0.0001).](BMRI2020-2419163.006){#fig6}

![qPCR analysis of circRNA expression levels in MAP and MAP after treatment including hsa_circRNA_101015, hsa_circRNA_101211, and hsa_circRNA_103470 (^*∗*^*P* \< 0.05; ^*∗∗∗*^*P* \< 0.001; ^*∗∗∗∗*^*P* \< 0.0001).](BMRI2020-2419163.007){#fig7}

![ROC analysis of hsa_circRNA_101015, hsa_circRNA_101211,and hsa_circRNA_103470 in MAP patients versus control group.](BMRI2020-2419163.008){#fig8}

![The ceRNA network of 6 differentially expressed circRNAs including hsa_circRNA_101015; hsa_circRNA_103470; hsa_circRNA_059665; hsa_circRNA_002532; hsa_circRNA_101211; hsa_circRNA_104156.](BMRI2020-2419163.009){#fig9}

###### 

Demographic and clinical characteristics of the MAP patients, SAP patients, and the control group.

  Characteristic   Control (*n* = 30)   MAP (*n* = 30)   SAP (*n* = 30)   *P* ^a^   *P* ^b^
  ---------------- -------------------- ---------------- ---------------- --------- ---------
  Age (y)          48.01 ± 12.67        48.26 ± 15.24    49.21 ± 10.32               
  F/M (*n*)        15/15                12/18            13/17                       
  MCTSI                                 1.4 ± 0.93       4.98 ± 1.04      \<0.001   \<0.001
  apache-ii                             3.09 ± 2.94      9.87 ± 4.01      \<0.001   \<0.001
  BISAP                                 0.91 ± 0.69      2.64 ± 1.01      \<0.001   \<0.001

^a^SAP versus control; ^b^SAP versus MAP.

###### 

Primers for circRNA and mRNA levels in qPCR.

  -----------------------------------------------------------------------------
  Target ID            Primer sequence, 5′-3′              Product size in bp
  -------------------- ----------------------------------- --------------------
  *β*-actin (human)    F: 5′GTGGCCGAGGACTTTGATTG 3′\       73
                       R: 5′ CCTGTAACAACGCATCTCATATT 3′    

  hsa_circRNA_002532   F: 5′TGGGAGTTTTCTGCTGATGAT 3′\      119
                       R: 5′ GGGTTTCTTTCTCATCTCTCTCA 3′    

  hsa_circRNA_101015   F: 5′ TATTGCCTTAGATCCTTCAAGTG 3′\   78
                       R: 5′ TAGCATCAACCAATCGCAAGT 3′      

  hsa_circRNA_101211   F: 5′ TGGTGGACGCATTTTCAGC 3′\       87
                       R: 5′ TCAGCACTTTGGTTAATCTTTCA 3′    

  hsa_circRNA_103470   F: 5′ TAACACGCTGGCCCATTACAAG 3′\    69
                       R: 5′ GTCCAGGTCCCGAAGGATGTAG 3′     

  hsa_circRNA_059665   F: 5′ AGACGCCTCCAGATGCCCTT 3′\      103
                       R: 5′ ACCAGACTGCAGGGACGGTGT 3′      

  hsa_circRNA_104156   F: 5′ AGAACTTCCTCGCACTGTGA 3′\      83
                       R: 5′ GGGAGCTATGTGAACGAACG 3′       
  -----------------------------------------------------------------------------

###### 

25 upregulated in patients with AP (FDR, false discover rate; FC, fold change).

  CircRNA              Alias              *P* value     FDR           FC (abs)    Chrom   best_transcript   Gene symbol
  -------------------- ------------------ ------------- ------------- ----------- ------- ----------------- -------------
  hsa_circRNA_001747   hsa_circ_0000246   0.014721747   0.999852393   1.5883102   chr10   uc009xqp.1        MCU
  hsa_circRNA_000761   hsa_circ_0000761   0.032659244   0.999852393   1.6521444   chr17   NM_032875         FBXL20
  hsa_circRNA_092519   hsa_circ_0001233   0.031884015   0.999852393   1.6043929   chr22   NM_020831         MKL1
  hsa_circRNA_102674   hsa_circ_0053932   0.004725614   0.999852393   1.5060131   chr2    NM_000627         LTBP1
  hsa_circRNA_020354   hsa_circ_0020354   0.016055616   0.999852393   1.5389787   chr10   NM_001329         CTBP2
  hsa_circRNA_059060   hsa_circ_0059060   0.020943584   0.999852393   1.6047327   chr2    NM_004404         SEPT2
  hsa_circRNA_074183   hsa_circ_0074183   0.038344155   0.999852393   1.5310808   chr5    NM_199189         MATR3
  hsa_circRNA_101015   hsa_circ_0000378   0.023899101   0.999852393   2.5012237   chr12   NM_002336         LRP6
  hsa_circRNA_100089   hsa_circ_0010501   0.017554998   0.999852393   1.7280045   chr1    NM_001397         ECE1
  hsa_circRNA_101386   hsa_circ_0004008   0.033240163   0.999852393   1.6859948   chr14   NM_014982         PCNX
  hsa_circRNA_101788   hsa_circ_0038872   0.036463254   0.999852393   1.68241     chr16   NM_004320         ATP2A1
  hsa_circRNA_103470   hsa_circ_0067301   0.049994992   0.999852393   2.2660602   chr3    NM_015103         PLXND1
  hsa_circRNA_006296   hsa_circ_0006296   0.049042374   0.999852393   2.11451     chr1    NM_004284         CHD1L
  hsa_circRNA_073748   hsa_circ_0073748   0.04252091    0.999852393   1.7548801   chr5    NM_005573         LMNB1
  hsa_circRNA_100891   hsa_circ_0023685   0.006324353   0.999852393   1.6050939   chr11   NM_002576         PAK1
  hsa_circRNA_404746                      0.036733957   0.999852393   1.5850621   chr10   NM_018590         CSGALNACT2
  hsa_circRNA_005899   hsa_circ_0005899   0.040331215   0.999852393   1.5983183   chr1    NM_000081         LYST
  hsa_circRNA_101584   hsa_circ_0036200   0.018409954   0.999852393   1.7862666   chr15   NM_002654         PKM
  hsa_circRNA_103448   hsa_circ_0067029   0.014194703   0.999852393   1.7205437   chr3    NM_006810         PDIA5
  hsa_circRNA_004077   hsa_circ_0004077   0.008137346   0.999852393   1.9160136   chr16   NM_020927         VAT1L
  hsa_circRNA_001363   hsa_circ_0000172   0.031341076   0.999852393   1.5314787   chr1    ENST00000340006   CSRP1
  hsa_circRNA_081881   hsa_circ_0081881   0.015325331   0.999852393   1.6956771   chr7    NM_002736         PRKAR2B
  hsa_circRNA_007037   hsa_circ_0007037   0.023032396   0.999852393   1.5823312   chr9    NM_024617         ZCCHC6
  hsa_circRNA_101211   hsa_circ_0029407   0.03202411    0.999852393   2.2688595   chr12   uc001uhy.1        GLT1D1
  hsa_circRNA_101833   hsa_circ_0039908   0.04884264    0.999852393   1.9258456   chr16   NM_017803         DUS2
  hsa_circRNA_100868   hsa_circ_0023255   0.026079049   0.999852393   1.6328345   chr11   NM_001876         CPT1A

###### 

26 downregulated circRNAs in patients with AP (FDR, false discover rate; FC, fold change).

  CircRNA              Alias              *P* value     FDR           FC (abs)    Chrom   best_transcript   Gene symbol
  -------------------- ------------------ ------------- ------------- ----------- ------- ----------------- -------------
  hsa_circRNA_102783   hsa_circ_0007532   0.006107722   0.999852393   1.6128104   chr2    NM_015341         NCAPH
  hsa_circRNA_101147   hsa_circ_0028255   0.04131669    0.999852393   1.6696469   chr12   NM_002973         ATXN2
  hsa_circRNA_407250                      0.047617993   0.999852393   1.668651    chr9    NM_004269         MED27
  hsa_circRNA_104923   hsa_circ_0002303   0.029109485   0.999852393   1.545763    chr9    NM_001006617      MAPKAP1
  hsa_circRNA_003912   hsa_circ_0003912   0.007972547   0.999852393   1.5662106   chr19   NM_001352         DBP
  hsa_circRNA_406493                      0.035076882   0.999852393   1.5155585   chr4    ENST00000508171   LIN54
  hsa_circRNA_104156   hsa_circ_0001626   0.009445502   0.999852393   1.9847946   chr6    NM_021813         BACH2
  hsa_circRNA_100485   hsa_circ_0006635   0.030459921   0.999852393   1.5844839   chr1    NM_014801         PCNXL2
  hsa_circRNA_102288   hsa_circ_0046702   0.022518826   0.999852393   1.7462888   chr18   NM_005433         YES1
  hsa_circRNA_003910   hsa_circ_0003910   0.032896633   0.999852393   2.0304476   chr3    ENST00000470751   SUMF1
  hsa_circRNA_000756   hsa_circ_0000756   0.024633983   0.999852393   1.7492495   chr17   NM_024857         ATAD5
  hsa_circRNA_059665   hsa_circ_0059665   0.02380009    0.999852393   3.2119391   chr20   NM_015600         ABHD12
  hsa_circRNA_103902   hsa_circ_0006916   0.016212163   0.999852393   1.637866    chr5    NM_004272         HOMER1
  hsa_circRNA_101495   hsa_circ_0003838   0.025961386   0.999852393   1.5569843   chr15   NM_173500         TTBK2
  hsa_circRNA_002149   hsa_circ_0001627   0.008793528   0.999852393   1.8600357   chr6    ENST00000343122   BACH2
  hsa_circRNA_405389                      0.02592997    0.999852393   1.5178686   chr15   NM_004255         COX5A
  hsa_circRNA_101899   hsa_circ_0000724   0.042899134   0.999852393   2.0353244   chr16   NM_017566         KLHDC4
  hsa_circRNA_103772   hsa_circ_0008910   0.048867847   0.999852393   1.6283164   chr4    NM_001921         DCTD
  hsa_circRNA_001124   hsa_circ_0001124   0.023465588   0.999852393   1.7343183   chr2    NM_032329         ING5
  hsa_circRNA_003553   hsa_circ_0003553   0.020016881   0.999852393   1.5533047   chr1    NM_013441         RCAN3
  hsa_circRNA_002532   hsa_circ_0002532   0.029871425   0.999852393   1.8331005   chrX    TCONS_00017187    XLOC_008000
  hsa_circRNA_102306   hsa_circ_0046995   0.016459014   0.999852393   1.9022111   chr18   NM_032142         CEP192
  hsa_circRNA_048000   hsa_circ_0048000   0.04965674    0.999852393   1.6658957   chr18   NM_198531         ATP9B
  hsa_circRNA_027904   hsa_circ_0027904   0.02618334    0.999852393   1.6835986   chr12   NM_020244         CHPT1
  hsa_circRNA_101898   hsa_circ_0040786   0.035050956   0.999852393   1.8735586   chr16   NM_017566         KLHDC4
  hsa_circRNA_100993   hsa_circ_0002484   0.032886032   0.999852393   1.519562    chr11   NM_014155         ZBTB44
  hsa_circRNA_040792   hsa_circ_0040792   0.046578567   0.999852393   1.8944367   chr16   NM_017566         KLHDC4

[^1]: Academic Editor: Kui Li
